Howe & Rusling’s Twist Bioscience TWST Stock Holding History

Howe & Rusling’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30	Closed	-$1K	–	1162
2022 Q1	$1K	Hold	30	–	–	﹤0.01%	967
2021 Q4	$2K	Hold	30	–	–	﹤0.01%	888
2021 Q3	$3K	Buy	+30	New	+$3.44K	﹤0.01%	810
2021 Q1	–	Sell	-10	Closed	-$1K	–	1018
2020 Q4	$1K	Buy	+10	New	+$1.11K	﹤0.01%	903

Other funds holding TWST

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Howe & Rusling's TWST Position: Q2 2022 in Review

Howe & Rusling sold out of Twist Bioscience (TWST) in Q2 2022, closing a stake of 30 shares — an estimated $1K sold.

Howe & Rusling first reported a position in TWST in Q4 2020 and held it in 4 quarters. The position peaked at $3K in Q3 2021. 204 funds tracked by Wall St. Rank hold TWST as of Q2 2022.

Howe & Rusling reported no remaining Twist Bioscience position as of Q2 2022 after selling out during the quarter.
Howe & Rusling sold 30 Twist Bioscience shares in Q2 2022, an estimated $1K.
Howe & Rusling first reported a position in Twist Bioscience in Q4 2020 and held it in 4 quarters.
Howe & Rusling's Twist Bioscience position peaked at $3K in Q3 2021.
204 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2022.

Based on Howe & Rusling's 13F filing for Q2 2022, filed 15 Aug 2022.